Perimenopause Partner and Family Role: A Complete Guide
At a glance
- Direct evidence / Family support may reduce stigma around menopause mental health [1]
- Symptom duration / Frequent hot flashes lasted a median of 7.4 years; 4.5 years past the final period [2]
- Depression risk / Twice as likely to develop significant depressive symptoms after entering perimenopause, in women with no prior depression [3]
- Sleep / 26% met insomnia criteria in a review; hot flashes linked to night awakenings [4]
- Best-supported treatment / Hormone therapy for hot flashes, night sweats and genitourinary symptoms [5]
- Pregnancy / Still possible during perimenopause [6][7]
What is happening
Perimenopause is the years before the final period. Menopause is reached after 12 months in a row with no period; the transition usually starts in the 40s and lasts about 4 years on average, up to 10 [6][7]. Pregnancy is still possible throughout, even with skipped periods [7].
Hot flashes last years, not months
In SWAN, which followed 3,302 women at 7 US sites, frequent hot flashes or night sweats lasted a median of 7.4 years. Among women with an observable final period, they persisted a median of 4.5 years after it [2]. Expecting symptoms to pass in a few months does not match this timeline.
Sleep and mood
A review of sleep across the transition reports that 26% of women have symptoms severe enough to meet criteria for insomnia, and that hot flashes are linked with awakenings recorded on sleep studies [4]. In the Harvard Study of Moods and Cycles, 460 premenopausal women aged 36 to 45 with no lifetime diagnosis of major depression were followed; those who entered perimenopause were twice as likely to develop significant depressive symptoms as women who stayed premenopausal, after adjustment for age and negative life events [3].
Treatment facts worth knowing
Hormone therapy remains the most effective treatment for hot flashes and night sweats and for genitourinary symptoms of menopause, and it prevents bone loss and fracture [5]. The Premarin label says that when estrogen is prescribed for a woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer [8].
FDA asked on 10 November 2025 for the cardiovascular, breast cancer and probable dementia statements to be removed from boxed warnings, and on 12 February 2026 approved changes for a first group of six products; the endometrial cancer box is retained for systemic estrogen-alone products [9][10][11]. Many labels still carry the old box, including the Premarin label effective 2026-06-04 and the Prempro label effective 2026-04-28 [8][12].
Bleeding after menopause
Vaginal bleeding after menopause is not normal [7]. The Premarin label says adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken for undiagnosed persistent or recurring abnormal genital bleeding in postmenopausal women [8].
Frequently asked questions
Does partner support help?
How long does perimenopause last?
Can someone still get pregnant during perimenopause?
Did FDA remove the hormone therapy warnings?
Is bleeding after menopause normal?
References
- Khadilkar S, Divakar H, Benedetto C, Genazzani A, Ramos D, Argale E, et al. FIGO best practice recommendations for the mental health of women at menopausal age. Int J Gynaecol Obstet. 2026;173(2):588-601. FIGO best practice recommendations for the mental health of women at menopausal age
- Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-9. Duration of menopausal vasomotor symptoms over the menopause transition
- Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63(4):385-90. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles
- Baker FC, de Zambotti M, Colrain IM, Bei B. Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nat Sci Sleep. 2018;10:73-95. Sleep problems during the menopausal transition: prevalence, impact, and management challenges
- “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. The 2022 hormone therapy position statement of The North American Menopause Society
- Menopause | Menopause Symptoms | MedlinePlus. Menopause | Menopause Symptoms | MedlinePlus
- Menopause basics | Office on Women's Health. Menopause basics | Office on Women's Health
- U.S. National Library of Medicine, DailyMed. Premarin oral tablets (still older boxed warning) (estrogens, conjugated) prescribing information. Premarin oral tablets (still older boxed warning) (estrogens, conjugated) label
- U.S. Food and Drug Administration. U.S. Food and Drug Administration
- FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA
- HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy | FDA. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy | FDA
- U.S. National Library of Medicine, DailyMed. Prempro / Premphase (conjugated estrogens and medroxyprogesterone acetate) prescribing information. Prempro / Premphase (conjugated estrogens and medroxyprogesterone acetate) label